[Top][All Lists]

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

The St0ck to Watch

From: Terri Bray
Subject: The St0ck to Watch
Date: Wed, 18 Aug 2004 10:48:25 +0000

                        The Growth St0ck Report
                             Breaking News!
           Genex Pharmaceuticals (OTCBB: GENX) Press Release
   Genex Pharmaceutical Sees StrOng Earnings Gr0wth for 2004 and 2005

                     Tuesday August 17, 10:26 am ET                             
NEW YORK--(BUSINESS  WIRE)--Aug.  17,  2004--Genex  Pharmaceutical, Inc.
(stock symbol: GENX),a Delaware corporation, is a profitable  biomedical
technology   company   with   a  unique  product  for  treating  various
bone-related  injuries  called   Reconstituted   Bone  Xenograft  (RBX).
Approved by the Chinese Food & Drug Administration, RBX is suitable  for
compound   or   complex   bone   fractures,  compression  fractures  and
intractable  fractures,  bone   defects,   vertebral   column  or  joint
rehabilitation and for bone absence after tumor removal such as  a  bone
cyst.  The  company  announced  financial results for its second quarter
ending June 30, 2004. The  following  are  some of the highlights in its
recent quarterly filing with the SEC:

432% in-crease in revenue for Q2 2004 compared to Q2 2003.

874% in-crease in revenue for 6 months ended June 30, 2004  compared  to
same period last year.

Significant  in-crease in net inc0me for Q2 2004 compared to Q2 2003 and
for the 6 month period ended  June  30,  2004 as compared to same period
last year.

380% in-crease in Gr0ss Pr0fit for Q2 2004 compared to Q2 2003.

840% in-crease in Gr0ss Pr0fit for 6 months ended June 30, 2004 compared
to same period last year.

"We are seeing significant  in-creases  in revenues and pr0fitability as
we respond to growing customer demand for RBX. We see continued earnings
momentum for 2004 and 2005," said Chairman and Chief Executive Mr. Fuzhi

           (Press Release Source: Genex Pharmaceutical, Inc.)


                    About Genex Pharmaceutical, Inc.

Genex Pharmaceutical,  Inc.  is  a  biomedical  technology  company with
distinctive proprietary technology for an orthopedic device that  treats
bone-related  injuries.  Headquartered  in  Tianjin,  China, the Company
manufactures and distributes Reconstituted  Bone Xenograft (RBX), to 400
hospitals in 22 provinces throughout mainland China. RBX offers a modern
alternative to traditional methods of treating orthopedic injuries.

              Good Luck and Succesful Trading. Go GENEX!!

DISCL-AIMER:  Information within  this  em-ail contains "F0RWARD looking
statements" within the meaning of Section 27A of the Securities  Act  of
1933  and  Section  21B  of  the  Securities  Exchange  Act of 1934. Any
statements  that  express  or   involve   discussions  with  respect  to
predictions,  expectations,  beliefs,  plans,  projections,  objectives,
goals, assumptions or future events or performance are not statements of
historical fact and may be "F0RWARD looking statements."F0RWARD  looking
statements  are  based on expectations, estimates and projections at the
time the  statements  are  made  that  involve  a  number  of  risks and
uncertainties which could cause  actual  results  or  events  to  differ
materially  from those presently anticipated. F0RWARD looking statements
in this action  may  be  identified  through  the  use  of words such as
"projects", "foresee", "expects",  "will,"  "anticipates,"  "estimates,"
"believes,"  "understands"  or  that  by  statements  indicating certain
actions "may," "could," or "might" occur. As with many micro-cap stocks,
today's company has additional risk  factors worth noting. Those factors
include:a limited operating  history,  the  company  advancing  cash  to
related  parties  and a shareholder on an unsecured basis: one vendor, a
related party  through  a  majority  stockholder,  supplies ninety-seven
percent of the company's raw materials:  reliance on two  customers  for
over  fifty  percent  of  their  business  and  numerous  related  party
transactions  and the need to raise capital.These factors and others are
more fully spelled out in the company's SEC filings. We urge you to read
the those filings before you  invest.  The  Growth ST0CK Report does not
represent that the information contained  in  this  message  states  all
material  facts  or  does not omit a material fact necessary to make the
statements therein not misleading.  All information provided within this
em-ail pertaining to investing, ST0CKS, securities must be understood as
information provided and not investment advice. The Growth ST0CK  Report
advises  all  readers  and  subscribers to seek advice from a registered
professional  securities  representative  before  deciding  to  trade in
ST0CKS featured within this ema-il. None of  the  material  within  this
report   shall  be  construed  as  any  kind  of  investment  advice  or
solicitation.Many of these companies are on the verge of bankruptcy. You
can lose all your M0NEY by investing in this ST0CK. The publisher of The
Growth ST0CK Report is not  a registered investment ADVIS0R. Subscribers
should  not  view  information  herein  as  legal,  tax,  accounting  or
investment advice. Any reference to past performance(s) of companies are
specially selected to be referenced based on the  favorable  performance
of these companies. You would need perfect timing to acheive the results
in  the  examples  given.   There can be no assurance of that happening.
Remember, as always,  past  performance  is  never  indicative of future
results and a thorough due diligence effort, including  a  review  of  a
company's filings, should be completed prior to investing. In compliance
with  the  Securities Act of 1933, Section 17(b),The Growth ST0CK Report
discloses the receipt  of  twelve  thousand  D0LLARS  from a third party
(DMI,Inc.), not an officer, director or affiliate  shareholder  for  the
circulation  of  this report. DMI, Inc. has a position in the ST0CK they
will sell at any time without  notice.  Be aware of an inherent conflict
of interest resulting from such compensation due to the fact  that  this
is  a paid adver-tisement and we are conflicted. All factual information
in this report  was  gathered  from  public  sources,  including but not
limited to Company Websites, SEC Filings and Company Press Releases. The
Growth ST0CK Report believes this information to  be  reliable  but  can
make  no  guarantee  as  to  its  accuracy  or  completeness. Use of the
material within this em-ail constitutes your acceptance of these terms.

reply via email to

[Prev in Thread] Current Thread [Next in Thread]